Acute phase treatment of venous thromboembolism: advanced therapy

Summary

Venous thromboembolism, which encompasses deep-vein thrombosis and acute pulmonary embolism (PE), represents a major contributor to global disease burden worldwide. For patients who present with cardiogenic shock or persistent hypotension (acute high-risk PE), there is consensus that immediate reperfusion treatment applying systemic fibrinolysis or, in the case of a high bleeding risk, surgical or catheterdirected techniques, is indicated. On the other hand, for the large, heterogeneous group of patients presenting without overt haemodynamic instability, the indications for advanced therapy are less clear. The recently updated guidelines of the European Society of Cardiology emphasise the importance of clinical prediction rules in combination with imaging procedures (assessment of right ventricular function) and laboratory biomarkers (indicative of myocardial stress or injury) for distinguishing between an intermediate and a low risk for an adverse early outcome. In intermediate-high-risk PE defined by the presence of both right ventricular dysfunction on echocardiography (or computed tomography) and a positive troponin (or natriuretic peptide) test, the bleeding risks of full-dose fibrinolytic treatment have been shown to outweigh its potential clinical benefits unless clinical signs of haemodynamic decompensation appear (rescue fibrinolysis). Recently published trials suggest that catheter-directed, ultrasoundassisted, low-dose local fibrinolysis may provide an effective and particularly safe treatment option for some of these patients.

Keywords

Pulmonary embolism - risk-adjusted treatment - fibrinolysis - catheter-directed treatment - pharmacomechanical therapy

• References

• 1 Raskob GE, Angchaisuksiri P, Blanco AN. et al. Thrombosis: A major contributor to global disease burden. Thromb Haemost 2014; 112: 843-852.
• 2 Cohen AT, Agnelli G, Anderson FA. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
• 3 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389.
• 4 Kasper W, Konstantinides S, Geibel A. et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997; 30: 1165-1171.
• 5 Kasper W, Konstantinides S, Geibel A. et al. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997; 77: 346-349.
• 6 British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 1992; 340: 873-876.
• 7 Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI. et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-1245.
• 8 Aujesky D, Jimenez D, Mor MK, Geng M, Fine MJ, Ibrahim SA. Weekend versus weekday admission and mortality after acute pulmonary embolism. Circulation 2009; 119: 962-968.
• 9 Laporte S, Mismetti P, Decousus H. et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 2008; 117: 1711-1716.
• 10 Konstantinides S, Goldhaber SZ. Pulmonary embolism: risk assessment and management. Eur Heart J 2012; 33: 3014-3022.
• 11 Konstantinides SV, Torbicki A, Agnelli G. et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)Endorsed by the European Respiratory Society (ERS). Eur Heart J 2014; 35: 3033-3073.
• 12 Aujesky D, Obrosky DS, Stone RA. et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172: 1041-1046.
• 13 Aujesky D, Roy PM, Verschuren F. et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011; 378: 41-48.
• 14 Jimenez D, Aujesky D, Moores L. et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170: 1383-1389.
• 15 Righini M, Roy PM, Meyer G. et al. The Simplified Pulmonary Embolism Severity Index (PESI): validation of a clinical prognostic model for pulmonary embolism. J Thromb Haemost 2011; 09: 2115-2117.
• 16 Lankeit M, Gomez V, Wagner C. et al. A strategy combining imaging and laboratory biomarkers in comparison with a simplified clinical score for risk stratification of patients with acute pulmonary embolism. Chest 2012; 141: 916-922.
• 17 Kreit JW. The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. Chest 2004; 125: 1539-1545.
• 18 Coutance G, Cauderlier E, Ehtisham J. et al. The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a meta-analysis. Crit Care 2011; 15: R103.
• 19 Sanchez O, Trinquart L, Colombet I. et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J 2008; 29: 1569-1577.
• 20 Becattini C, Agnelli G, Germini F. et al. Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis. Eur Respir J 2014; 43: 1678-1690.
• 21 Kucher N, Boekstegers P, Muller OJ. et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129: 479-486.
• 22 Meyer G, Vicaut E, Danays T. et al. Fibrinolysis for patients with intermediaterisk pulmonary embolism. N Engl J Med 2014; 370: 1402-1411.
• 23 Becattini C, Agnelli G, Salvi A. et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 2010; 125: e82-e86.
• 24 Lankeit M, Jimenez D, Kostrubiec M. et al. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 2011; 124: 2716-2724.
• 25 Lankeit M, Jimenez D, Kostrubiec M. et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014; 43: 1669-1677.
• 26 Dellas C, Tschepe M, Seeber V. et al. A novel H-FABP assay and a fast prognostic score for risk assessment of normotensive pulmonary embolism. Thromb Haemost 2014; 111: 996-1003.
• 27 Lankeit M, Dellas C, Benz V. et al. The predictive value of heart-type fatty acidbinding protein is independent from symptom duration in normotensive patients with pulmonary embolism. Thromb Res 2013; 132: 543-547.
• 28 Becattini C, Casazza F, Forgione C. et al. Acute pulmonary embolism: external validation of an integrated risk stratification model. Chest 2013; 144: 1539-1545.
• 29 Jimenez D, Kopecna D, Tapson V. et al. Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2014; 189: 718-726.
• 30 Bova C, Sanchez O, Prandoni P. et al. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. Eur Respir J 2014; 44: 694-703.
• 31 Miller GA, Sutton GC, Kerr IH. et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Heart J 1971; 33: 616.
• 32 The urokinase pulmonary embolism trial. A national cooperative study. Circulation 1973; 47: II1-II108.
• 33 Tibbutt DA, Davies JA, Anderson JA. et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonay embolism. Br Med J 1974; 01: 343-347.
• 34 Ly B, Arnesen H, Eie H. et al. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978; 203: 465-470.
• 35 Marini C, Di Ricco G, Rossi G. et al. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988; 54: 162-173.
• 36 Levine M, Hirsh J, Weitz J. et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98: 1473-1479.
• 37 Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. Chest 1990; 97: 528-533.
• 38 Dalla-Volta S, Palla A, Santolicandro A. et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 1992; 20: 520-526.
• 39 Goldhaber SZ, Haire WD, Feldstein ML. et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341: 507-511.
• 40 Tebbe U, Bramlage P, Graf A. et al. Desmoteplase in acute massive pulmonary thromboembolism. Thromb Haemost 2009; 101: 557-562.
• 41 Tebbe U, Graf A, Kamke W. et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 1999; 138: 39-44.
• 42 Meneveau N, Seronde MF, Blonde MC. et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 2006; 129: 1043-1050.
• 43 Daniels LB, Parker JA, Patel SR. et al. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80: 184-188.
• 44 Konstantinides S. Clinical practice. Acute pulmonary embolism. N Engl J Med 2008; 359: 2804-2813.
• 45 Kline JA, Nordenholz KE, Courtney DM. et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost 2014; 12: 459-468.
• 46 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-e494S.
• 47 Jaff MR, McMurtry MS, Archer SL. et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123: 1788-1830.
• 48 Wan S, Quinlan DJ, Agnelli G. et al. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004; 110: 744-749.
• 49 Marti C, John G, Konstantinides S. et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2014. Epub ahead of print
• 50 Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med 2012; 125: 465-470.
• 51 Rose PS, Punjabi NM, Pearse DB. Treatment of right heart thromboemboli. Chest 2002; 121: 806-814.
• 52 Chartier L, Bera J, Delomez M. et al. Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients. Circulation 1999; 99: 2779-2783.
• 53 Konstantinides S, Tiede N, Geibel A. et al. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol 1998; 82: 966-970.
• 54 Konstantinides S, Geibel A, Heusel G. et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143-1150.
• 55 Kanter DS, Mikkola KM, Patel SR. et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997; 111: 1241-1245.
• 56 Sors H, Pacouret G, Azarian R. et al. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994; 106: 712-717.
• 57 Goldhaber SZ, Kessler CM, Heit JA. et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 1992; 20: 24-30.
• 58 Meyer G, Sors H, Charbonnier B. et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism [see comments]. J Am Coll Cardiol 1992; 19: 239-245.
• 59 Goldhaber SZ, Kessler CM, Heit J. et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; 02: 293-298.
• 60 Verstraete M, Miller GA, Bounameaux H. et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77: 353-360.
• 61 Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study. J Am Med Assoc 1974; 229: 1606-1613.
• 62 Konstantinides S, Marder VJ. Thrombolysis in venous thromboembolism. In: Hemostasis and Thrombosis. Philadelphia: Lippincott Williams and Wilkins; 2006. pp. 1317-1329.
• 63 Mikkola KM, Patel SR, Parker JA. et al. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J 1997; 134: 69-72.
• 64 Wang C, Zhai Z, Yang Y. et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 2010; 137: 254-262.
• 65 Sharifi M, Bay C, Skrocki L. et al. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am J Cardiol 2013; 111: 273-277.
• 66 Armstrong PW, Gershlick AH, Goldstein P. et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013; 368: 1379-1387.
• 67 Leacche M, Unic D, Goldhaber SZ. et al. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg 2005; 129: 1018-1023.
• 68 Delnoij TS, Accord RE, Weerwind PW. et al. Atrial trans-septal thrombus in massive pulmonary embolism salvaged by prolonged extracorporeal life support after thrombo-embolectomy. A bridge to right-sided cardiovascular adaptation. Acute Card Care 2012; 14: 138-140.
• 69 Leick J, Liebetrau C, Szardien S. et al. Percutaneous circulatory support in a patient with cardiac arrest due to acute pulmonary embolism. Clin Res Cardiol 2012; 101: 1017-1020.
• 70 Taniguchi S, Fukuda W, Fukuda I. et al. Outcome of pulmonary embolectomy for acute pulmonary thromboembolism: analysis of 32 patients from a multicentre registry in Japan. Interact Cardiovasc Thorac Surg 2012; 14: 64-67.
• 71 Malekan R, Saunders PC, Yu CJ. et al. Peripheral extracorporeal membrane oxygenation: comprehensive therapy for high-risk massive pulmonary embolism. Ann Thorac Surg 2012; 94: 104-108.
• 72 Myers PO, Bounameaux H, Panos A. et al. Impending paradoxical embolism: systematic review of prognostic factors and treatment. Chest 2010; 137: 164-170.
• 73 Engelberger RP, Kucher N. Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review. Eur Heart J 2014; 35: 758-764.
• 74 Engelberger RP, Moschovitis A, Fahrni J. et al. Fixed low-dose ultrasound-assisted catheter-directed thrombolysis for intermediate-and high-risk pulmonary embolism. Eur Heart J 2015; 36: 597-604.
• 75 Braaten JV, Goss RA, Francis CW. Ultrasound reversibly disaggregates fibrin fibers. Thromb Haemost 1997; 78: 1063-1068.
• 76 Francis CW, Blinc A, Lee S. et al. Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. Ultrasound Med Biol 1995; 21: 419-424.
• 77 Kuo WT, Gould MK, Louie JD. et al. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol 2009; 20: 1431-1440.